Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a, Open-Label, Multiple-Cohort, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54- VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)

Next Previous
Trial Profile

A Phase 1/2a, Open-Label, Multiple-Cohort, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54- VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABI 110 (Primary)
  • Indications Polypoidal choroidal vasculopathy; Wet age-related macular degeneration
  • Focus Adverse reactions
  • Sponsors Avirmax Biopharma

Most Recent Events

  • 03 Feb 2025 According to an Avirmax Biopharma media release, Roger A. Goldberg, M.D., M.B.A., Principal Investigator of this Phase 1/IIa trial.
  • 03 Feb 2025 According to an Avirmax Biopharma media release, company announced completion of the first cohort of this Phase I/IIa clinical trial of ABI-110.
  • 21 Nov 2024 According to an Avirmax Biopharma media release, the first patient has been successfully dosed in the Phase I/IIa clinical trial of ABI-110, the company's first gene therapy drug for the treatment of Wet Age-related Macular Degeneration (AMD) including Polypoidal Choroidal Vasculopathy (PCV).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top